PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16371460-4	2006	Exposure of melanoma cells and tumors to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in the degradation of mutant B-Raf, inhibition of mitogen-activated protein kinase activation and cell proliferation, induction of apoptosis, and antitumor activity.	tanespimycin	61-99	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	137-142	
18281615-0	2008	17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.	tanespimycin	0-6	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	68-73	
18281615-0	2008	17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.	tanespimycin	0-6	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	95-100	
18281615-1	2008	PURPOSE: The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) has been shown to have promising results in antitumor activity through the degradation of the activated V600E mutant of B-Raf (V600E B-Raf) in cutaneous melanoma cell lines.	tanespimycin	29-67	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	197-202	
18281615-1	2008	PURPOSE: The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) has been shown to have promising results in antitumor activity through the degradation of the activated V600E mutant of B-Raf (V600E B-Raf) in cutaneous melanoma cell lines.	tanespimycin	69-75	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	197-202	
18375819-2	2008	BRAF that is activated by the common V600E and other mutations, as well as by upstream NRAS mutations, has been shown to require the molecular chaperone heat shock protein 90 (HSP90) for stabilization and is depleted by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)].	tanespimycin	240-278	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	0-4	
18676857-2	2008	Previous studies have shown that 17-AAG/DMAG treatment induces the degradation of mutant BRAF (V600E) and inhibits the activation of mitogen-activated protein/extracellular signal-regulated kinase 1/2 (MEK1/2).	tanespimycin	33-39	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	89-93	
16322212-0	2005	Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.	tanespimycin	83-121	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	10-15